Iron overload is inevitable in patients who are transfusion dependent. In young children with transfusion-dependent thalassemia (TDT), current practice is to delay the start of iron chelation therapy due to concerns over toxicities, which have been observed when deferoxamine was started too early. However, doing so may increase the risk of iron accumulation that will be manifested as toxicities later in life. This study investigated whether deferiprone, a chelator with a lower affinity for iron than deferoxamine, could postpone transfusional iron overload while maintaining a good safety profile. Recently diagnosed TDT infants (N 5 64 their age ranged from 10 to 18 (median 12) months, 54.7% males; receiving 6 transfusions; serum ferittin (SF) >400 to < 1000 ng/mL were randomized to "early start deferiprone" (.ES-DFP) at a low dose (50 mg/kg/ day) or to "delay chelation" (DC), and remained in the study until their serum ferritin (SF) level reached 1000 lg/L. 61 patients continued the study Levels of transferrin saturation (TSAT) and labile plasma iron (LPI) were measured as well. By approximately 6 months postrandomization, 100% of the subjects in DC group had achieved SF > 1000 mg/L and TSAT > 70% compared with none in the ES-DFP group. LPI level > 0.6 mM was observed in 97% vs. 40% of the DS and ES groups, respectively, (P < 0.001). The time to reach SF > 1000 mg/L was delayed by 6 months in the ES-DFP group (P < 0.001) without escalating DFP dose. No unexpected, serious, or severe adverse events were seen in the ES-DFP group.
| I N TR ODU C TI ON
Iron overload is the main risk factor for morbidity and mortality in patients with transfusion dependent thalassemia (TDT). Thus, life-long iron chelation therapy is necessary for prevention of morbidities and for their long term survival. Iron chelation therapy is generally safe in pediatric TDT patients [1] [2] [3] [4] but deferoxamine (DFO) use in very young children with only mild iron overload has been associated with growth delay and significant bone defects due to excessive depletion of iron needed for normal biologic reactions. 5 Delaying the start of treatment until a more severe level of iron load was reached was found to be effective in minimizing the risk of DFO-induced toxicities. Accordingly, current practice is to start chelation therapy only after receipt of 10-20 red blood cell transfusions or when serum ferritin (SF) levels rise above 1000 lg/L. 9 However, while this delay minimizes the risk of DFO toxicities, it may increase the risk of nontransferrin bound iron (NTBI) and labile plasma iron (LPI) loading in endocrine glands and heart, where toxicities could manifest later in life. 7, 8 Deferasirox (DFX), currently approved for use in children 2 years of age and older, is an alternative to DFO, but it should only be considered when the patient has been transfused with at least 100 mL/kg of packed red blood cells and has a serum ferritin level consistently greater than 1000 lg/L.
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Compared to DFX and DFO, the oral chelator deferiprone (DFP) has a more physiological affinity for iron (pFe31 log stability constant of 19.9 vs. 22.5 for DFX and 26.6 for DFO), an attribute that enables the transfer of iron from sites of excess to normal biologic receptors, Clinical Trials.gov Identifier: NCT 02173951
The current trial was conducted in young children with newly diagnosed TDT. It was designed to evaluate the number of blood transfusions associated with the appearance of excess LPI, excess TSAT, and elevation of serum ferritin, and to evaluate whether the early use of a low dose of DFP could postpone the appearance of those indices while maintaining a good safety profile.
| M E TH ODS
This was an open-label, single center, randomized, prospective study designed to evaluate the safety and tolerability of the early use of DFP in young children with TDT, and to evaluate if DFP use could postpone or prevent iron overload in this patient population. A secondary objective was to determine the relationship between the number of blood transfusions and the severity of iron overload. The study was approved by the ethical committee of Ain Shams University, and was conducted according to the principles of the Declaration of Helsinki. Written informed consent for each patient was obtained from both parents prior to any study procedures being carried out. Period of recruitment was 16 months; starting from August 2014
The main inclusion criteria were (1) a confirmed diagnosis of TDT, as determined by high performance liquid chromatography, (2) confirmed transfusion-dependency and initiation of a regular regimen of red blood cell (RBC) transfusions to maintain Hb > 9 g/dL, but receipt to date of no more than 1000 mL of packed red blood cells, (3) no prior receipt of iron chelation therapy, and (4) levels of LPI < 0.2 lM, TSAT < 70%, and SF < 400 lg/L. The main exclusion criteria were a diagnosis of hepatitis B or C, serum transaminases levels >5 times the upper normal limit, and a history of severe neutropenia/agranulocytosis (absolute neutrophil count <0.5 3 10 9 /L. Other criteria of exclusion were chronic diarrhea, evidence of potential noncompliance, and unwilling to join the study).
Enrollments of all patients were performed after verification of the inclusion and exclusion criteria. Once enrolled into the study, the children were monitored monthly until SF > 400 lg/L was reached, at which time, infants aged range 10-18 (median 12) months were randomized to "early start deferiprone" (ES-DFP) at 16. lg/L at any time during the study, testing was repeated 4 weeks later.
As soon as an SF value 1000 lg/L was confirmed, the patient was withdrawn from the study and started on a standard chelation regimen of deferiprone 75 mg/kg/day (i.e., for patients who were already receiving deferiprone, the dosage was increased from 50 to 75 mg/kg/ day).
Capillary CBCs were used when there was no crossmatch or trans- quantitative data between the two groups. Mann-Whitney U test was used for analysis of median levels of ANC in both groups throughout the study. The time to reaching SF 1000 lg/L was evaluated using the Kaplan-Meier survival curve and the log rank test was used to compare the Kaplan-Meier curve of the two groups. P value < 0.0001 was considered statistically significant.
| R E SU LTS
Disposition of patients is presented in Figure 1 . A total of 67 prospective participants were screened, of whom 3 were not eligible due to SF levels greater than 400 lg/L. The 64 enrolled patients were randomized in a 1:1 ratio to the two arms. Three patients (4.7%) withdrew early and were included only in the baseline analyses: the parents of a DC patient withdrew consent a week after enrollment, and 1 patient in each group was lost to follow-up 2 weeks after baseline. No patients in either arm withdrew due to adverse events. There were no significant differences between the ES-DFP and DC groups with respect to months of age at diagnosis of TDT (6.6 6 1.4 vs. 6.9 6 1.6, respectively), at first transfusion (8. /L. All episodes of neutropenia resolved within 7 days. The median and range of ANC over the course of the study for both groups are presented in Table 1 . ALT levels in ES-DFP patients ranged from 12 to 153 U/L and returned to baseline levels with continued DFP therapy. All adverse events were mild in severity and did not necessitate interruption of chelation in the ES-DFP group, including those who experienced neutropenia. With the exception of one patient in each group who missed a single LPI sampling, all patients completed all laboratory assessments. The missing values were not extrapolated. Table 2 shows the results of the analyses conducted throughout the trial. At baseline, SF, TSAT, and LPI levels were all similar between the groups (P > 0.05). 
| D I SCUSSION
Human body lacks an active mechanism to excrete the excess iron associated with repeated red blood cell transfusions. Over time, excess iron causes multiple endocrine abnormalities and liver and cardiac failure, and has been associated with increased risk of neoplasia. 21 Chelation therapy aims to prevent this toxicity. Optimal iron levels in patients with transfusion-dependent anemias have been based on measurement of serum ferritin and on liver and cardiac iron concentrations. 22 However, more recent data suggest that the focus of chelation should be the reduction of more reactive forms of iron, such as the labile iron pool in plasma and cells. 23 In very young children, iron chelation therapy requires a delicate balance between prevention of iron toxicity while at the same time minimizing the risk of iron depletion. Deferiprone may be an appropriate agent for early chelation therapy, given its ability to remove excess iron from macrophages and the good safety profile associated with its long-term use in patients without systemic iron overload. 18, 19, 24 The current study provides the first indication that early start of deferiprone therapy can reduce the increase in serum ferritin, saturation of transferrin, and the appearance of labile plasma iron in children newly diagnosed with TDT, without apparent clinical manifestations of iron- depletion toxicity. The incidence of neutropenia was consistent with that observed in young children who participated in a population-based study, 25 and there was no difference in its incidence between patients in the ES-DFP and DC groups. These findings are consistent with previous reports that episodes of mild neutropenia during deferiprone use are not necessarily a sign of impending agranulocytosis and do not require discontinuation of therapy. 17, 26, 27 However, in the interest of safety, we consider it to be appropriate to temporarily interrupt deferiprone in all cases of neutropenia, and restart it upon resolution. Other adverse events associated with deferiprone use were also mild in severity and did not necessitate interruption of therapy, and no unexpected or serious adverse events were observed. However, a longer period of observation in a greater number of patients is warranted to fully establish the safety profile of deferiprone in young children with mild iron overload.
The results from this study show that LPI values correlated significantly with those of TSAT, SF, and the number of blood transfusions, as had been previously shown. 28 While a level of LPI 0.6 mM appeared as early as after 5 transfusions in the DC patients, it was delayed to at least 10 transfusions with DFP therapy. Similarly, a TSAT level 70% appeared after 10 transfusions in DC children and was delayed to at least 17 transfusions with DFP therapy. On the basis of the SF measure, all DC patients included in the current study were withdrawn by 6 months, whereas in the ES-DFP group, only one patient had reached the criterion for withdrawal at 9 months and the remainder did not reach it until 12 months (16-18 transfusions). The data demonstrate that delaying initiation of chelation therapy until a child has received 10 or more transfusions promotes transferrin saturation and excessive LPI, and its practice should be reconsidered.
It has been observed that in TDT patients in whom the iron load has been reduced, rates of mortality and morbidity are decreased compared to those seen in heavily iron-loaded patients. Effective and complete treatment of transfusional iron overload could be achieved if chelation protocols could eliminate excess iron without causing iron 
